WO2001062786A2 - Tlp peptides and dna sequences coding the same - Google Patents
Tlp peptides and dna sequences coding the same Download PDFInfo
- Publication number
- WO2001062786A2 WO2001062786A2 PCT/EP2001/001857 EP0101857W WO0162786A2 WO 2001062786 A2 WO2001062786 A2 WO 2001062786A2 EP 0101857 W EP0101857 W EP 0101857W WO 0162786 A2 WO0162786 A2 WO 0162786A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tlp
- peptides
- peptide
- nucleic acid
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 32
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 title description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 239000002299 complementary DNA Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000008001 CAPS buffer Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- -1 injectables Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to DNA molecules encoding peptides derived from proteins of the TLP complex. More specifically, the invention is directed to a cDNA sequence coding for a peptide of the 100 kDa TLP complex.
- TLP Tumor Liberated Particles
- protein complexes present in human tumor cells, particularly in lung carcinoma are indicated. TLPs were isolated for the first time from tumor tissues following the procedure disclosed in EP283433. Afterwards, certain proteins forming the TLP complexes were identified. A 214 kDa TLP protein prevalently expressed in lung carcinoma is disclosed in Oncology, 1983, 40:248-253. Epitopes specific for that protein and antibodies against it are disclosed in
- EP649433 discloses a lOOkDa protein isolated from lung carcinoma, as well as immunogenic peptides derived therefrom.
- the peptide RTNKEASI was used to produce polyclonal antibodies recognizing the lOOkDa TLP complex.
- Such antibodies were used for the characterisation of the TLP expression pattern in tissues of different origin and for the validation of the same protein as tumor marker (W098/15282).
- the study of TLP expression in different tumor cell lines has revealed similar expression levels among cell lines derived from breast carcinoma (MCF7) and colorectal carcinoma (HT29).
- chemotherapeutic agents were shown to increase the expression of TLP antigen in a tumor cell population (NSCLC), whereas the lOOkDa TLP protein, as well as the peptides derived therefrom, lymphocytes with specific antitumor effects (W098/15282).
- the inventors have obtained the cDNA sequence encoding a peptide of the lOOkDa TLP complex, as described hereafter.
- Lysates of tumor cells expressing TLP were prepared, from which the total RNA was -extracted and then subjected to RT-PCR with pairs of oligonucleotide primers having degenerate sequences corresponding to the TNKEASI peptide (forward primer) and, respectively, random hexanucleotide sequences (reverse primer).
- the amplification product was cloned in a suitable vector and then sequenced. Inside it, an ORF of 300 bases was identified, whose sequence is reported in SEQ ID N. 1. The amino acid sequence encoded by the ORF is reported in SEQ ID N. 2.
- the invention provides a nucleic acid molecule comprising the sequence SEQ ID N. 1 , the variants thereof due to genetic code degeneration, and the nucleic acid molecules hybridising to the complementary strand of SEQ ID N. 1 under stringent conditions.
- the invention further comprises an expression vector that contains a nucleic acid molecule herein disclosed.
- the vector can be a plasmid. cosmid, virus, bacteriophage, or any other vector commonly used in genetic techniques, which, in addition to the coding sequence, may comprise control elements, such as sequences regulating the transcription, including start and stop codons, -> j enhancers, promoters, signal sequences and the like.
- the invention comprises eukaryotic or prokaryotic cells transfected or transformed with said vector.
- TLP protein The complete sequence of a TLP protein enables m vitro preparations of large quantities of it by genetic engineering
- the availability of such antigen preparations allows for deep investigations on the role of TLP m human malignancy It also enables the preparation of an assay for early diagnosis of the corresponding tumors and the generation of a specific a i cancer vaccine.
- a further aspect of the invention relates to a peptide encoded by the DNA sequence of SEQ ID N. 1 , as reported in SEQ ID N. 2, or a fragment thereof.
- Such peptides can be prepared with recombmant DNA procedures, using the desc ⁇ bed cDNA, or with chemical synthesis, following known procedures (e.g. see “Mer ⁇ field, ( 1986) Science 232:341-347", or “Barany and Mer ⁇ field, 1979, The peptides, Gross and Meienhofer, eds NY Academic Press, 1-284”). The synthesis can be earned out in solution or m solid phase w th an automatic synthesizer.
- One or more ammo acid residues can be replaced by different L- or D-residues, so as to maintain the immunogenic effects, or they can be chemically modified, for instance by amidation of the carboxy terminus, by linking hpophilic groups (e.g. mynstyl), or by glycosylation or conjugation with other peptides, in order to improve properties like immunogenicity, selectivity of induction of the immune response or bioavailabihty after administration.
- the peptides can also be chemically denvatized on their lateral chains, for instance on free carboxy groups, to form salts, esters, hydrazides.
- said peptides can be conjugated to known epitopes m order to induce a higher cytotoxic or helper immune response against tumors.
- the immunogenic activity of the peptides can be easily determined by means of in vitro tests, for instance using t-lymphocyte propagation or proliferation essays (Protti M.P. et al., 1990, J. Immunol. 144: 1711-1720), cytotoxicity essays (Protti M. P. et al., 1996, Cancer Res. 56: 1210-1213), or binding essays with
- the peptides derived from SEQ ID N are identical to SEQ ID N.
- TLP-specific antibodies are used to generate TLP-specific antibodies.
- the latter can be monoclonal or polyclonal- and recognize the TLP epitopes specific for the peptides herein disclosed.
- Such antibodies are preferably used in immunoessays to detect TLP expression in tumors.
- the invention provides the use of the above nucleic acid molecules or peptides for the preparation of a pharmaceutical composition for the preventive or therapeutic treatment of tumors, especially of lung tumors.
- a typical application involving the use of the cDNA is the preparation of DNA vaccines, which can be effected as taught in US5593972 or
- the peptides can also be used in combination with different chemotherapeutic agents, which are known to increase the effects thereof
- compositions in accordance with the invention contain an effective amount of DNA or peptides together with pharmaceutically acceptable excipients.
- effective amount is meant the amount sufficient to activate lymphocytes and to trigger a cellular or humoral response against tumors.
- the pharmaceutical compositions are used in the preventive vaccination of subjects with susceptibility to neoplasias or in the therapeutic vaccination of neoplastic patients.
- the term "vaccination" in this context is referred either to the active vaccination, i.e. the in vivo administration of the peptides or cDNA to activate the immune response directly in the patient, or to the passive vaccination, i.e. the use of peptides for the in vitro activation of
- T cytotoxic lymphocytes and their subsequent re-inoculation in the patient T cytotoxic lymphocytes and their subsequent re-inoculation in the patient.
- the procedures for the preparation and use of vaccines are known to anyone skilled in the art; an extensive description is given for example in Paul, Fundamental
- Vaccines are usually prepared in form of solutions, injectables, suspensions, but also in form of solid or liposome- based preparations.
- the immunogenic ingredients can be mixed with pharmaceutically acceptable excipients, such as emulsifiers, buffering agents, adjuvants, so as to increase the vaccine effectiveness.
- pharmaceutically acceptable excipients such as emulsifiers, buffering agents, adjuvants, so as to increase the vaccine effectiveness.
- RNAs were extracted from several cell lines (HT-29, SAOS-2, A 549, MCF-7, H23, H157, H1819, WI38) with RNAzol B reagent (TEL-TEST, INC) and reverse transcribed using the Reverse Transcription System (PROMEGA). Polymerase chain reaction (PCR) was carried out for 35 cycles (1 min at 95°C, 2 min at 40°C and 1 min at 72°C) using an upstream degenerate oligonucleotide: ACN AAY AAR GAR GCN TCN ATH TC, that corresponds to the amino acid sequence RTNKEASI and Random Hexamers as the downstream primer. PCR products were electrophoresed on a 1% agarose gel containing ethidium bromide.
- PCT products were cloned in the pGEM-T easy vector (PROMEGA)
- Rabbit anti-TLP serum was obtained by immunizing four rabbits subcutaneously with 0.5 mg of the peptide of SEQ ID N. 2, in 0.5 ml of phosphate -buffered saline (PBS), mixed with 0.5 ml of Freund's complete adjuvant. Booster injections with incomplete adjuvant were given at 2-week intervals. Sera were collected on alternate weeks via ear vein bleeds. Titers of antisera were performed by radioimmunoassay on 96-well microtiter plates. Wells were coated with a fixed concentration of peptide antigen, washed, and incubated with various dilutions of sera.
- PBS phosphate -buffered saline
- the bound immunoglobuline was detected with 125 I-labeled protein A and quantified by radioimmunoassay. At a dilution of 1 : 1,000, all sera showed a positive staining reaction with the peptide antigen. Preimmune sera from the corresponding rats were also tested and non significant reactivity was detected.
- Western Blot Tumor cell lysates were prepared by resuspending pelletted cells in 200 ⁇ l lysis buffer (SOmMTris, 5mM EDTA, 250 mM Na Cl, 50 mM NaF, 0.1% Triton, 0.1 mM Na3V04, plus protease inhibitors). 50 ⁇ g of protein extract was run on a 8% polyacrylamide gel. Proteins within the polyacrylamide gel were transferred to a PVDF membrane (Millipore) in CAPS buffer (10 mM CAPS, 20% methanol, pH 11). The membrane was blocked with 5% milk in TBS-T buffer (2mM Tris,
- ECL system (Dupont NEN). A specific staining was detected in correspondence of the tumor cell lysates. Preimmune sera and control lysates did not show a significant-reactivity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU40634/01A AU4063401A (en) | 2000-02-25 | 2001-02-20 | Tlp peptides and dna sequences coding the same |
BR0108557-3A BR0108557A (pt) | 2000-02-25 | 2001-02-20 | Peptìdeos de tlp e sequências de dna codificando os mesmos |
CA002401031A CA2401031A1 (en) | 2000-02-25 | 2001-02-20 | Tlp peptides and dna sequences coding the same |
KR1020027010999A KR20020086564A (ko) | 2000-02-25 | 2001-02-20 | Tlp 펩티드 및 그를 암호화하는 dna 서열 |
US10/204,635 US20030157116A1 (en) | 2000-02-25 | 2001-02-20 | Tlp peptides and dna sequences coding the same |
EP01911660A EP1265917A2 (en) | 2000-02-25 | 2001-02-20 | Tlp peptides and dna sequences coding the same |
JP2001562567A JP2003523759A (ja) | 2000-02-25 | 2001-02-20 | Tlpペプチドならびにそれをコードするdna配列 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000MI000344A IT1317853B1 (it) | 2000-02-25 | 2000-02-25 | Peptidi tlp e sequenze di dna che li codificano. |
ITMI2000A000344 | 2000-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001062786A2 true WO2001062786A2 (en) | 2001-08-30 |
WO2001062786A3 WO2001062786A3 (en) | 2002-01-17 |
Family
ID=11444175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/001857 WO2001062786A2 (en) | 2000-02-25 | 2001-02-20 | Tlp peptides and dna sequences coding the same |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1265917A2 (ko) |
JP (1) | JP2003523759A (ko) |
KR (1) | KR20020086564A (ko) |
AU (1) | AU4063401A (ko) |
BR (1) | BR0108557A (ko) |
CA (1) | CA2401031A1 (ko) |
IT (1) | IT1317853B1 (ko) |
RU (1) | RU2002122722A (ko) |
WO (1) | WO2001062786A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006070432A2 (en) | 2004-12-30 | 2006-07-06 | Vito Michele Fazio | Anti-tumoral immunogenic peptides and vaccine thereof |
ITRM20100256A1 (it) * | 2010-05-19 | 2011-11-20 | Farmafin Spa | Un nuovo biomarcatore per la diagnosi precoce e l'immunoterapia del cancro |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998015282A1 (en) * | 1996-10-09 | 1998-04-16 | Unihart Corporation | Immunogenic tlp composition |
US5877294A (en) * | 1992-07-03 | 1999-03-02 | Instituto Farmacoterapico Italiano S.P.A. | Antigenic regions of tumor-liberated particles (TLP) complexes and antibodies against the same |
-
2000
- 2000-02-25 IT IT2000MI000344A patent/IT1317853B1/it active
-
2001
- 2001-02-20 EP EP01911660A patent/EP1265917A2/en not_active Withdrawn
- 2001-02-20 BR BR0108557-3A patent/BR0108557A/pt not_active Application Discontinuation
- 2001-02-20 JP JP2001562567A patent/JP2003523759A/ja active Pending
- 2001-02-20 WO PCT/EP2001/001857 patent/WO2001062786A2/en not_active Application Discontinuation
- 2001-02-20 KR KR1020027010999A patent/KR20020086564A/ko not_active Application Discontinuation
- 2001-02-20 RU RU2002122722/13A patent/RU2002122722A/ru unknown
- 2001-02-20 CA CA002401031A patent/CA2401031A1/en not_active Abandoned
- 2001-02-20 AU AU40634/01A patent/AU4063401A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877294A (en) * | 1992-07-03 | 1999-03-02 | Instituto Farmacoterapico Italiano S.P.A. | Antigenic regions of tumor-liberated particles (TLP) complexes and antibodies against the same |
WO1998015282A1 (en) * | 1996-10-09 | 1998-04-16 | Unihart Corporation | Immunogenic tlp composition |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL [Online] AC006410, 18 January 1999 (1999-01-18) EVANS, G. A. ET AL.: "Homo sapiens" XP002173802 * |
DATABASE EMBL [Online] AL358433, 7 June 2000 (2000-06-07) PAVITT, R.: "Human DNA sequence" XP002173803 * |
TARRO G ET AL: "ANTIGENIC REGIONS OF TUMOR LIBERATED PROTEIN (TLP) COMPEXES AND ANTIBODIES AGAINST THE SAME" BIOMEDICINE AND PHARMACOTHERAPY,FR,ELSEVIER, PARIS, vol. 47, 1 December 1993 (1993-12-01), page 290 XP002046354 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006070432A2 (en) | 2004-12-30 | 2006-07-06 | Vito Michele Fazio | Anti-tumoral immunogenic peptides and vaccine thereof |
US9150627B2 (en) | 2004-12-30 | 2015-10-06 | Vito Michele Fazio | Anti tumoral immunogenic peptides and vaccine thereof |
ITRM20100256A1 (it) * | 2010-05-19 | 2011-11-20 | Farmafin Spa | Un nuovo biomarcatore per la diagnosi precoce e l'immunoterapia del cancro |
WO2011145125A1 (en) * | 2010-05-19 | 2011-11-24 | Farmafin Spa | Chimeric biomarker for the early diagnosis and immunotherapy of cancer |
Also Published As
Publication number | Publication date |
---|---|
IT1317853B1 (it) | 2003-07-15 |
ITMI20000344A1 (it) | 2001-08-25 |
EP1265917A2 (en) | 2002-12-18 |
WO2001062786A3 (en) | 2002-01-17 |
ITMI20000344A0 (it) | 2000-02-25 |
JP2003523759A (ja) | 2003-08-12 |
CA2401031A1 (en) | 2001-08-30 |
AU4063401A (en) | 2001-09-03 |
BR0108557A (pt) | 2003-04-29 |
KR20020086564A (ko) | 2002-11-18 |
RU2002122722A (ru) | 2004-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0529023B1 (en) | Therapeutically useful peptides and peptides fragments | |
US10166276B2 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
US7939646B2 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
JP4130359B2 (ja) | Wt1特異的免疫療法のための組成物および方法 | |
TWI285648B (en) | Compositions and methods for WT1 specific immunotherapy | |
AU2006261342B2 (en) | Her-2 peptides | |
ES2278436T3 (es) | Antigenos de estreptococos del grupo b. | |
EP1988097A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
MXPA02006934A (es) | Composiciones y metodos para la terapia y diagnostico de cancer de prostata. | |
ES2304398T3 (es) | Antigeno de tumores. | |
ES2533493T3 (es) | Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato | |
Schultz‐Thater et al. | MAGE‐1 gene product is a cytoplasmic protein | |
EP1265917A2 (en) | Tlp peptides and dna sequences coding the same | |
US20030157116A1 (en) | Tlp peptides and dna sequences coding the same | |
WO2005048943A2 (en) | Compositions and methods for synergistic induction of antitumor immunity | |
RU2383620C2 (ru) | ПЛАЗМИДЫ, КОДИРУЮЩИЕ ВАРИАНТЫ ПОСЛЕДОВАТЕЛЬНОСТИ БЕЛКА p185neu, И ИХ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
CN117177766A (zh) | 疫苗平台 | |
US20080107662A1 (en) | Immunogenic Peptides, Nucleic Acids Encoding The Same And Use Thereof In Cancer Treatment And Diagnosis | |
CN1404527A (zh) | Tlp肽以及编码它们的dna序列 | |
JP2002372532A (ja) | Htlv−i腫瘍に対する抗腫瘍抗原又はその抗原エピトープ | |
AU777474B2 (en) | Immunogenic peptides and the use thereof | |
EP4366763A1 (en) | Coronavirus vaccines | |
EP1806403A2 (en) | Human cancer antigen NY ESO 1/CAG-3 and gene encoding same | |
Torabi-Pour et al. | Identification and quantification of antigens associated with HLA class I molecules on a bladder tumour cell line: Implications for vaccine design | |
WO2001032193A1 (en) | Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 562567 Kind code of ref document: A Format of ref document f/p: F Ref country code: RU Ref document number: 2002 2002122722 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027010999 Country of ref document: KR Ref document number: 018054757 Country of ref document: CN Ref document number: 40634/01 Country of ref document: AU Ref document number: 2401031 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001911660 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027010999 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10204635 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001911660 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001911660 Country of ref document: EP |